Chongqing Genrix Biopharmaceutical (SH:688443) Ge Long Hui·2025-09-22 11:37Core Insights - The company, Zhixiang Jintai, has signed exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings and RXILIENT MEDICAL for two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and market access in various regions [1][2]. Group 1: Agreement Details - The agreements include upfront payments and milestone payments, with potential earnings of up to approximately RMB 260 million for GR2001 and RMB 250 million for GR1801 [1][2]. - Kangzhe will hold exclusive commercialization rights for both products in mainland China, while RXILIENT will have exclusive licensing rights in the Asia-Pacific region and the Middle East and North Africa [1][2]. Group 2: Product Information - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal heavy chain of Tetanus Neurotoxin (TeNT), classified as a Class 1 therapeutic biological product, providing passive immunity by blocking TeNT entry into neurons [2]. - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the Rabies Virus (RABV), also classified as a Class 1 therapeutic biological product, designed to prevent rabies by blocking the virus from binding to receptors before the active immunity from rabies vaccines takes effect [3].